Detalhe da pesquisa
1.
Prevalence of persistent SARS-CoV-2 in a large community surveillance study.
Nature
; 626(8001): 1094-1101, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38383783
2.
SARS-CoV-2, influenza A/B and respiratory syncytial virus positivity and association with influenza-like illness and self-reported symptoms, over the 2022/23 winter season in the UK: a longitudinal surveillance cohort.
BMC Med
; 22(1): 143, 2024 Mar 26.
Artigo
Inglês
| MEDLINE | ID: mdl-38532381
3.
Lineage replacement and evolution captured by 3 years of the United Kingdom Coronavirus (COVID-19) Infection Survey.
Proc Biol Sci
; 290(2009): 20231284, 2023 10 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37848057
4.
Addressing health inequalities in diabetes through research: Recommendations from Diabetes UK's 2022 health inequalities in diabetes workshop.
Diabet Med
; 40(4): e15024, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36508339
5.
Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom.
Clin Infect Dis
; 75(1): e329-e337, 2022 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34748629
6.
Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom.
Clin Infect Dis
; 2022 Aug 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35917440
7.
Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom.
N Engl J Med
; 385(27): 2582-2585, 2021 12 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34879193
8.
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
Nat Commun
; 15(1): 1008, 2024 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38307854
9.
Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022-23.
J Infect
; 88(6): 106164, 2024 Apr 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38692359
10.
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Sci Rep
; 13(1): 8441, 2023 05 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37231004
11.
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Nat Commun
; 14(1): 2799, 2023 05 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37193713
12.
Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance.
Lancet Reg Health Eur
; 13: 100282, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34927119
13.
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
Nat Med
; 28(5): 1072-1082, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35165453
14.
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.
Nat Commun
; 13(1): 3748, 2022 06 29.
Artigo
Inglês
| MEDLINE | ID: mdl-35768431
15.
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
Nat Med
; 27(12): 2127-2135, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34650248
16.
Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time.
Elife
; 102021 07 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34250907
17.
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
Nat Med
; 27(8): 1370-1378, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34108716
18.
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.
Nat Commun
; 12(1): 6250, 2021 10 29.
Artigo
Inglês
| MEDLINE | ID: mdl-34716320
19.
Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.
Nat Microbiol
; 6(9): 1140-1149, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34290390